Text Size

The Effects of Sports Drinks on Urinary Lithogenicity

This study has been completed.
Sponsor:
Information provided by:
VA New York Harbor Healthcare System
ClinicalTrials.gov Identifier:
NCT00381277
First received: September 26, 2006
Last updated: February 18, 2011
Last verified: February 2011
History of Changes
  Purpose

The effect of sports drinks on the tendency to form kidney stones has not been assessed. Patients will drink 1 liter a day of 2 sports drinks and collect urine to determine changes in urine chemistry that may decrease the risk of forming stones.


Condition Intervention
Urolithiasis
 Drug: Gatorade
Drug: Performance

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: The Effects of Sports Drinks on Urinary Lithogenicity

Resource links provided by NLM:

MedlinePlus related topics: Kidney Stones
U.S. FDA Resources

Further study details as provided by VA New York Harbor Healthcare System:

Primary Outcome Measures:
  • Urinary supersaturation of calcium oxalate
  • Urinary citrate excretion
  • Urinary calcium excretion
  • Urinary sodium excretion

Estimated Enrollment: 10
Study Start Date: March 2006
Study Completion Date: September 2006
Primary Completion Date: March 2006 (Final data collection date for primary outcome measure)
Detailed Description:

Participants will drink 1 liter of water each day for one week in the control period, then 1 liter of sports drink each day for one week during the experimental period. Urine collections will be performed during both periods. Diet will be chosen by participants and a food diary will be kept so that participants can replicate diet during the urine collections.

  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • age 18-80 years old
  • men and women
  • able to sign informed consent

Exclusion Criteria:

  • history of kidney stones
  • bone disease
  • parathyroid disease
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00381277

Locations
United States, New York
New York Harbor VAMC
New York, New York, United States, 10010
Sponsors and Collaborators
VA New York Harbor Healthcare System
Investigators
Study Director: David S Goldfarb, MD New York Harbor VAMC
  More Information

Additional Information:
David S. Goldfarb, M.D.  This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party: David S Goldfarb MD, New York Harbor VA Medical Center
ClinicalTrials.gov Identifier: NCT00381277     History of Changes
Other Study ID Numbers: DG-1
Study First Received: September 26, 2006
Last Updated: February 18, 2011
Health Authority: United States: Institutional Review Board
United States: Federal Government

Keywords provided by VA New York Harbor Healthcare System:
nephrolithiasis
citrate
oxalate

Additional relevant MeSH terms:
Urolithiasis
Urologic Diseases

ClinicalTrials.gov processed this record on May 16, 2013